CARM1-mediated methylation of MED12 sensitizes breast cancer cells to 5-fluorouracil but not to RTK inhibitors, suggesting a unique mechanism of drug response modulation in breast cancer compared with NSCLC. Here, MED12 is linked to non-small cell lung carcinoma.